share_log

Comerica Bank Makes New Investment in ZimVie Inc. (NASDAQ:ZIMV)

Comerica Bank Makes New Investment in ZimVie Inc. (NASDAQ:ZIMV)

Comerica Bank 对ZimVie Inc.(纳斯达克股票代码:ZIMV)进行新投资
Defense World ·  2023/02/01 06:22

Comerica Bank purchased a new stake in shares of ZimVie Inc. (NASDAQ:ZIMV – Get Rating) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 16,019 shares of the company's stock, valued at approximately $110,000. Comerica Bank owned about 0.06% of ZimVie as of its most recent SEC filing.

Comerica Bank在向美国证券交易委员会发布的最新披露中称,该公司在第三季度购买了ZimVie Inc.(纳斯达克股票代码:ZIMV — Get Rating)的新股份。该机构投资者购买了该公司16,019股股票,价值约11万美元。截至最近向美国证券交易委员会提交的文件,Comerica Bank拥有ZimVie约0.06%的股份。

Several other institutional investors have also recently made changes to their positions in the business. US Bancorp DE bought a new stake in shares of ZimVie during the 3rd quarter valued at $36,000. Strs Ohio purchased a new stake in ZimVie in the third quarter worth about $47,000. Allspring Global Investments Holdings LLC bought a new position in shares of ZimVie in the third quarter worth about $71,000. Texas Permanent School Fund purchased a new position in shares of ZimVie during the 3rd quarter valued at about $148,000. Finally, Raymond James & Associates bought a new position in shares of ZimVie during the 3rd quarter valued at approximately $110,000. Institutional investors own 74.29% of the company's stock.

其他几位机构投资者最近也改变了他们在业务中的立场。美国Bancorp DE在第三季度购买了ZimVie的新股份,价值36,000美元。Strs Ohio在第三季度购买了ZimVie的新股份,价值约47,000美元。Allspring Global Investments Holdings LLC在第三季度购买了价值约71,000美元的ZimVie股票新德州永久学校基金在第三季度购买了ZimVie股票的新头寸,价值约14.8万美元。最后,Raymond James & Associates在第三季度购买了ZimVie股票的新头寸,价值约11万美元。机构投资者拥有该公司74.29%的股票。

Get
获取
ZimVie
ZimVi
alerts:
警报:

ZimVie Price Performance

ZimVie 价格表现

Shares of ZIMV stock opened at $9.81 on Wednesday. The stock's 50-day moving average price is $8.97 and its 200-day moving average price is $11.58. ZimVie Inc. has a 12-month low of $6.67 and a 12-month high of $50.40. The company has a quick ratio of 1.48, a current ratio of 2.51 and a debt-to-equity ratio of 0.76.

周三,ZIMV股票开盘价为9.81美元。该股的50天移动平均价格为8.97美元,其200天移动平均线价格为11.58美元。ZimVie Inc.创下12个月低点6.67美元,12个月高点为50.40美元。该公司的速动比率为1.48,流动比率为2.51,债务与权益比率为0.76。

ZimVie (NASDAQ:ZIMV – Get Rating) last issued its quarterly earnings data on Wednesday, November 9th. The company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.22. ZimVie had a negative return on equity of 2.75% and a negative net margin of 9.96%. The business had revenue of $214.58 million for the quarter, compared to analysts' expectations of $214.83 million. Analysts expect that ZimVie Inc. will post 1.95 earnings per share for the current year.
ZimVie(纳斯达克股票代码:ZIMV — Get Rating)上次发布季度收益数据是在11月9日星期三。该公司公布本季度每股收益(EPS)0.49美元,比市场普遍预期的0.27美元高出0.22美元。ZimVie的负股本回报率为2.75%,负净利润率为9.96%。该业务本季度的收入为2.1458亿美元,而分析师的预期为2.1483亿美元。分析师预计,ZimVie Inc.今年将公布每股收益1.95美元。

Analysts Set New Price Targets

分析师设定了新的价格目标

Separately, Barclays initiated coverage on shares of ZimVie in a research note on Wednesday, December 21st. They set an "underweight" rating and a $9.00 target price on the stock.

另外,巴克莱银行在12月21日星期三的一份研究报告中开始报道ZimVie的股票。他们为该股设定了 “减持” 评级和9.00美元的目标价格。

ZimVie Profile

ZimVie 简介

(Get Rating)

(获取评分)

ZimVie Inc, a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies.

ZimVie Inc是一家医疗技术公司,开发、制造和提供一系列产品和解决方案,旨在治疗一系列脊柱疾病,并为全球的牙齿置换和修复程序提供支持。它提供牙种植系统、假体和基台产品、手术器械和套件;骨移植、屏障膜、同种异体移植和胶原蛋白伤口护理产品;口内扫描仪;以及虚拟治疗计划服务、引导手术解决方案、CAD/CAM 工作流程系统、患者特异性修复组件和口内扫描仪,以及用于各种脊柱手术、生物制剂和骨愈合技术的脊柱融合植入物和仪器。

Read More

阅读更多

  • Get a free copy of the StockNews.com research report on ZimVie (ZIMV)
  • Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
  • Dividend King Sysco: Buying On The Dip
  • Is the 1,600% Rise in Genius Group Stock Justified?
  • After Further Review, Investors Liked Exxon Mobil's Earnings
  • Will Caterpillar Dig Its Way To Another Buying Opportunity?
  • 免费获取 StockNews.com 关于 ZimVie (ZIMV) 的研究报告的副本
  • Verizon、Charter在过去一个月中呈上升趋势:他们现在买了吗?
  • 股息之王 Sysco:逢低买入
  • Genius集团股票上涨1,600%是否合理?
  • 经过进一步审查,投资者喜欢埃克森美孚的收益
  • 卡特彼勒会挖掘另一个买入机会吗?

Want to see what other hedge funds are holding ZIMV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ZimVie Inc. (NASDAQ:ZIMV – Get Rating).

想看看还有哪些对冲基金持有 ZIMV 吗? 访问Holdingschannel.com,获取ZimVie Inc.(纳斯达克股票代码:ZIMV — 获取评级)的最新13F文件和内幕交易。

Receive News & Ratings for ZimVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZimVie and related companies with MarketBeat.com's FREE daily email newsletter.

接收 ZimVie Daily 的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收ZimVie及相关公司的最新新闻和分析师评级的简明每日摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发